Modeling microbial drug-resistance: from mathematics to pharmacoeconomics

by Yu. M. Gomon, M. A. Arepyeva, Yu. E. Balykina, A. S. Kolbin, A. A. Kurylev, M. A. Proskurin, S. V. Sidorenko
Published 2018-05-01

Pharmacoeconomic analysis of denosumab in patients with breast cancer and bone metastases

by A. S. Kolbin, A. A. Kurylev, M. A. Proskurin, Yu. E. Balykina
Published 2018-05-01

Pharmacoeconomic analysis of vemurafenib and dabrafenib use in patients with inoperable or metastatic melanoma with BRAF V600 mutation

by A. S. Kolbin, A. A. Kurylev, Yu. E. Balykina, M. A. Proskurin
Published 2018-05-01

An update of pharmacoeconomic analysis of trastuzumab emtanzine in patients with HER2+ breast cancer and central nervous system metastases

by A. S. Kolbin, A. A. Kurylev, Y. E. Balykina, M. A. Proskurin
Published 2019-04-01

Pharmacoeconomic analysis of trastuzumab emtanzine comparing to lapatinib + capecitabine in pa...

by A. S. Kolbin, A. A. Kurylev, Yu. E. Balykina, M. A. Proskurin, D. R. Naskhletashvili
Published 2018-05-01

Economic analysis of Lixisenatide in Diabetes Mellitus Type 2

by A. S. Kolbin, A. A. Mosikyan, A. A. Kurylev, Yu. E. Balykina, M. A. Proskurin, W. Zhao
Published 2018-05-01

FIRST RUSSIAN TYPE 2 DIABETES MELLITUS SIMULATION MODEL WITH DISCREET EVENTS MODELING. HEALTH-ECONOMIC ANALYSIS

by A. S. Kolbin, O. K. Khmelnitskiy, A. A. Kurylev, Yu. E. Balykina, M. A. Proskurin, E. P. Kolpak, M. V. Bure
Published 2015-03-01

HEALTH ECONOMIC ASSESSMENT OF ANTIRHEUMATIC DRUGS IN PATIENTS WITH REUMATHOID ARTHRITIS PROGRESSED AFTER METOTREXATE

by A. S. Kolbin, A. A. Kurylev, M. A. Proskurin, Yu. E. Balykina
Published 2016-12-01

The social-economic burden of spinal muscular atrophy in Russia

by A. S. Kolbin, D. V. Vlodavets, A. A. Kurylev, Yu. Ye. Balykina, M. A. Proskurin, S. A. Mishinova, O. Yu. Germanenko, N. Yu. Kolbina
Published 2021-02-01